The Ministry of Health warned: here's what to do when you buy a drug that can cause cancer

The Ministry of Health draws attention to patients taking drugs containing the active ingredient valsartan. Some patients have bought drugs that are already withdrawn from the market and the next time they go to a pharmacy, another drug manufacturer with the same active ingredient will be offered. According to the Deputy Minister of Health, Kristina Garuolienė, in all Member States of the European Union, withdrawal of drugs containing valsartan, an ingredient of poor quality, which began after the start of a urgent withdrawal procedure, has already been reported.

and shared this information with the other Member States and the European Medicines Agency in the prescribed manner. On the basis of this information, IERC has also initiated a procedure for removal of defective drugs from the Lithuanian pharmaceutical supply chain, including pharmacies.

The report identifies the role of pharmacies in solving the problems badociated with the disposal of poor quality valsartan medications. In cases where the patient introduces and wishes to return a defective product containing valsartan, the pharmacy must accept it as a pharmaceutical waste, including blister packs.

To prevent the patient from being interrupted or inconvenienced by the purchase of another quality product The prescription of a no prescription prescription for a recidivist patient for 30 days may be given to the patient.

The pharmacy, substituting the poor quality product for a qualitatively equivalent product, must take into account the fact that it is the manufacturer of poor quality drugs that is responsible. gap "We hope that joint efforts will not harm the supply of high-quality drugs with valsartan and that pharmacies will take all necessary measures," said Deputy Minister Kristina Garuolienė.

We also recommend that residents who use drugs containing valsartan consult a physician to badess the need for this drug and other therapeutic alternatives.

Currently, the European Medicines Agency, with the participation of the Directorate of Quality Medicines Health Care and national drug agencies of the EU Member States undertake a review and evaluation more of the Scartan group of drugs.

Reproduction of the news portal tv3.lt in the media and websites without the written permission of All Media Lithuania UAB is prohibited.